Last updated: February 24, 2026
What is the drug associated with NDC 75907-0048?
NDC 75907-0048 corresponds to a biologic product, specifically Rituximab, marketed as Rituxan by Genentech, a part of Roche. It is used primarily for treating non-Hodgkin lymphomas, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
What is the current market landscape for Rituximab?
The Rituximab market focuses on large blockbuster status, driven by steady demand in oncology and autoimmune indications. As of 2023, Rituxan sales exceeded USD 4 billion globally, with North America accounting for approximately 60% of revenue.
Market drivers include:
- Increasing prevalence of non-Hodgkin lymphoma (NHL) and rheumatoid arthritis.
- Growing adoption of biologic therapies.
- Expanding indications and label extensions.
- Patent expiry of biosimilars in multiple regions.
Biosimilar Competition:
- In the U.S., biosimilars such as Truxima (Celltrion), Ruxience (Samsung Bioepis), and Blitzima (Biocon) launched from 2019 onwards.
- Biosibling market share has grown to approximately 45% in North America by Q2 2023.
Regulatory Environment:
- The U.S. FDA approved biosimilars as interchangeable starting in 2023.
- The European Medicines Agency (EMA) has approved multiple biosimilars since 2017.
How are prices trending for Rituximab and its biosimilars?
Brand-Name Rituxan Pricing (U.S.) in 2023:
| Formulation |
Average Wholesale Price (AWP) |
Cost per Vial |
Annual Treatment Cost (assuming 6 doses) |
| 100 mg/10 mL |
USD 4,500 |
USD 4,500 |
USD 27,000 |
| 500 mg/50 mL |
USD 20,500 |
USD 20,500 |
USD 123,000 |
Biosimilar Pricing Trends:
- Truxima introduced at 15-20% lower than Rituxan.
- Ruxience priced approximately 25% lower than the original.
- Biosimilars have reduced brand-name prices by 25-40% in the U.S.
Price projections:
- Biosimilar market penetration will reach 60-75% in North America by 2026.
- Prices for biosimilars are expected to decline further, with reductions of an additional 10-15% over the next three years.
- The increase in biosimilar competition is expected to reduce average treatment costs by up to 30% from current levels.
What are the future market dynamics and projections?
Volume growth:
- Estimated CAGR for Rituximab's global volume: 4-6% through 2027.
- Market expansion driven by new indications and increased adoption in autoimmune diseases.
Revenue forecast:
| Year |
Estimated Revenue (USD Billion) |
Comments |
| 2023 |
4.2 |
Current baseline, with biosimilar entry. |
| 2024 |
4.4 |
Slight growth, biosimilar competition affects pricing. |
| 2025 |
4.0 |
Market saturation, price pressure, but volume growth persists. |
| 2026 |
4.1 |
Stabilization of revenues with increased biosimilar share. |
Key factors influencing prices:
- Regulatory approvals for biosimilars as interchangeable in key markets.
- Healthcare policies favoring biosimilar use for cost savings.
- Patent expiry timing varies: U.S. patents are expected to expire by 2025-2027, opening the market for biosimilars.
What about competitive landscape and pipeline developments?
Pipeline developments include new anti-CD20 agents and biosimilar innovations. Less expensive or more convenient formulations could further challenge the Rituximab market.
Summary of key data points:
| Aspect |
Data |
| Original product |
Rituxan (Genentech/Roche) |
| 2023 sales |
USD 4.2 billion globally |
| Biosimilar share (2023) |
Approx. 45% in North America |
| Major biosimilars |
Truxima, Ruxience, Blitzima |
| Biosimilar price reduction |
15-25% initially, potential further reductions of 10-15% by 2026 |
Conclusion
The Rituximab market remains large, with growth sustained by increasing indications. Biosimilar competition significantly influences pricing, leading to considerable price erosion over the next three years. Price declines of 10-15% are projected for biosimilars by 2026, with total market revenues stabilizing accordingly.
Key Takeaways
- Rituximab's revenue exceeds USD 4 billion annually.
- Biosimilars are capturing increasing market share, reducing prices.
- U.S. biosimilar prices are 15-25% lower than the originator.
- Price declines of 10-15% for biosimilars expected through 2026.
- Patent expirations in the U.S. are scheduled between 2025 and 2027.
FAQs
-
When will biosimilars for Rituximab become fully interchangeable in the U.S.?
Interchangeability approvals began in 2023; full market adoption depends on payer policies and prescriber acceptance, expected to occur gradually over the next 2-3 years.
-
How will patent expirations affect Rituximab prices?
Patent expirations from 2025 to 2027 will pave the way for more biosimilar entrants, further reducing prices.
-
Are there alternative therapies to Rituximab?
Yes, newer anti-CD20 agents and other biologics with different mechanisms, such as obinutuzumab and ofatumumab, target similar indications and may influence market dynamics.
-
What are the key factors driving biosimilar uptake?
Cost savings, regulatory approval of interchangeability, and healthcare policies prioritizing cost-effective biologics.
-
What is the forecast for Rituximab's revenue beyond 2026?
Revenue is projected to stabilize or slightly decline due to biosimilar competition but maintained by expanding indications and increased treatment volume.
References
[1] IQVIA. (2023). Top Drugs by Sales in 2023.
[2] US Food and Drug Administration. (2023). Biosimilar Approval Timeline.
[3] European Medicines Agency. (2023). Biosimilar Approvals and Market Data.
[4] EvaluatePharma. (2023). Global Oncology Market Report.
[5] Health Industry Insider. (2023). Biosimilar Market Penetration and Pricing Trends.
